Study findings published in JAMA Internal Medicine show that treatment initiation with statins is associated with an elevated risk for diabetes progression.
Discontinuing continuous glucose monitoring leads to the loss of approximately half of the additional time in glycemic range accrued during its use among people with type 2 diabetes, MOBILE study data show.
Reducing the cost of SGLT2 inhibitors by around 17% would make them cost-effective for use in people with type 2 diabetes in low- and middle-income countries, study findings indicate.
Chronic kidney disease is strongly associated with risk for cardiovascular disease events even in the absence of pre-existing vascular disease among people with type 2 diabetes, say researchers.
Insulin sensitivity may be associated with the likelihood of partial remission in children and adolescents newly diagnosed with type 1 diabetes, regardless of C-peptide levels and BMI, research suggests.
Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.
Response to vaccination against SARS-CoV-2 may be impaired in people with type 2 diabetes and poor glycemic control, but potentially improved if glucose levels are controlled, say researchers.
Dapagliflozin slows the long-term decline in estimated glomerular filtration rate, and reduces albuminuria, particularly in people with type 2 diabetes, report the DAPA-CKD investigators.
Flash glucose monitoring improves glycemic control and reduces diabetic ketoacidosis rates across nearly all age, sex, and sociodemographic strata, regardless of insulin pump use, according to UK observational data.
The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.
Many participants of DiRECT found reintroduction of food and subsequent weight-loss maintenance to be more challenging than the 800 calorie total meal replacement phase, the investigators report.
A dual-hormone fully closed-loop system did not demonstrate non-inferiority to a hybrid system in a randomized trial, despite producing a high time in range, report the researchers.
A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.
Both small and large nerve fiber impairment can be detected among people with well-controlled recent-onset type 1 or type 2 diabetes, and may regress with time, shows German research presented at the virtual 57th EASD Annual Meeting.
Semaglutide treatment results in significant reductions in levels of the inflammatory marker high-sensitivity C-reactive protein, indicates further analysis of the PIONEER and SUSTAIN trials.
Data from Scotland show that low socioeconomic status increases people’s risk for developing type 2 diabetes, while for those with type 1 diabetes it increases time spent with complications and reduces life expectancy.
Children and adults with type 1 diabetes achieve significant reductions in glycated hemoglobin and hypoglycemic events during their first 90 days of using the Omnipod DASH insulin pump system, show real-world data.
Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.
Findings from the SoliMix trial indicate that iGlarLixi may improve glycemic control with weight benefit compared with BIAsp 30 among people with suboptimally controlled type 2 diabetes on basal insulin.